— AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.
— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Products sales rose 8% year-over-year to $6.25 billion.
— Oncology sales advanced by 29% and respiratory sales grew by 13%. Biopharmaceuticals sales increased by 10% and new CVRM sales rose by 6% while sales in other medicines fell by 17%.
— Depending on the impact of the novel coronavirus (Covid-19) outbreak, AstraZeneca expects FY20 revenue to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage.
— Guidance assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus (Covid-19) outbreak.
— AZN stock, which advanced 4% in the last three months, was down slightly during the before-market session.
Most Popular
JetBlue Airways (JBLU) Q4 2022 Earnings: Key financials and quarterly highlights
JetBlue Airways Corporation (NASDAQ: JBLU) reported fourth quarter 2022 earnings results today. Total operating revenues increased 32% year-over-year to $2.4 billion. Net income amounted to $24 million, or $0.07
AAL Q4 2022 Report: Highlights American Airlines earnings
American Airlines Group (NASDAQ: AAL) announced fourth-quarter 2022 financial results on Thursday, reporting a sharp increase in revenues. The company turned profit from a loss last year. Total operating revenues
LUV Earnings: A snapshot of Southwest Airlines’ Q4 2022 report
Southwest Airlines Co. (NYSE: LUV) on Thursday announced financial results for the fourth quarter of 2022, reporting a net loss and a double-digit increase in revenues. Total operating revenue was
